Empagliflozin in South Asians with type 2 diabetes: Real world data on effects on cardiometabolic parameters, safety and determinants of response to therapy from a diabetes practice in Sri Lanka

SGLT2 inhibitors provide cardiovascular and renal protection in people with type 2 diabetes (T2DM). Real-world data on their effect on improving glucose and cardiovascular risk factors, and adverse effects in South Asians are limited.

Source: Primary Care Diabetes - November 29, 2022 Category: Primary Care Authors: Harsha Dissanayake, Shani Dilrukshi, Vithiya Ratnasamy, Pasindu Soysa, Thilina Samarathunga, Prabhath Bandara, Laksara De Silva, Prasad Katulanda Source Type: research